Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Tight Glycaemic Control During Cardiac Surgery (TGC)

This study has been terminated.
(Hypoglycaemia is significantly higher in TGC)
Information provided by:
Prince of Songkla University Identifier:
First received: July 29, 2010
Last updated: October 20, 2010
Last verified: August 2008

July 29, 2010
October 20, 2010
September 2008
March 2009   (final data collection date for primary outcome measure)
nosocomial infection [ Time Frame: within the first 30 day after surgery ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01225159 on Archive Site
morbidities and all causes mortality [ Time Frame: within the first 30 days after surgery ] [ Designated as safety issue: Yes ]
morbidities defined as hypoglycaemia (blood sugar less than 60 mg%), Stroke (focal neurological deficit confirmed with CT or MRI), acute renal failure (rising of creatinine)
Interleukin level [ Time Frame: before induction and at 4 hours after surgery ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Tight Glycaemic Control During Cardiac Surgery
Safety and Efficacy of Tight Glycaemic Control During Cardiac Surgery

To determine whether intraoperative tight glycaemic control can reduce postoperative infection, morbidity and mortality

Hyperglycaemia develops frequently in patients undergoing cardiac surgery, especially following cardiopulmonary bypass (CPB). Recent evidence suggests that acute hyperglycaemia adversely affects immune function, wound healing and cardiovascular function.

Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
Primary Purpose: Prevention
  • Nosocomial Infection
  • Interleukines
  • Glycemic Control
  • Cardiac Surgery With Cardiopulmonary Bypass Circuit
  • Drug: TGC blood sugar 80-150 mg%
    TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
    Other Name: intensive glycaemic control
  • Drug: Conventional glycaemic control
    Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
    Other Name: Control group
  • Experimental: Tight glycaemic control (TGC)
    Intervention: Drug: TGC blood sugar 80-150 mg%
  • No Intervention: Conventional glycaemic control
    Intervention: Drug: Conventional glycaemic control
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2009
March 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • age > 15 years
  • cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

  • active infection
  • insulin allergy
  • off-pump cardiopulmonary bypass procedures
15 Years and older
Contact information is only displayed when the study is recruiting subjects
SUB.EC 51-1008-08-1-1
Faculty of Medicine, Prince of Songkla University
Prince of Songkla University
Not Provided
Principal Investigator: Panthila Rujirojindakul, M.D. Faculty of Medicine, Prince of Songkla University
Prince of Songkla University
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP